Citi Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiranā¼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
August 30, 2024 6:00 AM EDTIn the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively
In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35%
Strong Trends of Additive Efficacy on Top of Tafamidis Across Primary and Secondary Endpoints
Demonstrated Statistically Significant Benefits on Multiple Measures of Disease Progression
Encouraging Safety and Tolerability Profile, Consistent with Established Profile... More
